AACP
RIGL icon

Advantage Alpha Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Advantage Alpha Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,804
Closed -$334K – 93
2025
Q3 		$334K Buy
+11,804
New +$353K 0.1% 116

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Advantage Alpha Capital Partners's RIGL Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 11,804 shares — an estimated $334K sold.

Advantage Alpha Capital Partners first reported a position in RIGL in Q3 2025 and held it in 1 quarter. The position peaked at $334K in Q3 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 11,804 Rigel Pharmaceuticals shares in Q4 2025, an estimated $334K.
  • Advantage Alpha Capital Partners first reported a position in Rigel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Rigel Pharmaceuticals position peaked at $334K in Q3 2025.
  • 193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.